SCHEMBL5230631

SCHEMBL5230631

COC(=O)C1(Cc2ccccc2)CN(C(=O)OC(C)(C)C)CCN1Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 1/20 0.43
OPRK1 P41145 1/20 0.43
GPR119 Q8TDV5 2/20 0.42
STS P08842 1/20 0.42
ACHE P22303 1/20 0.42
HDAC1 Q13547 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
CYP2D6 P10635 1/20 0.40
SCD O00767 1/20 0.40
SCD5 Q86SK9 1/20 0.40
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
BRD4 O60885 1/20 0.39
P2RX7 Q99572 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21731415 0.85 OPRD1 (0.44) OPRD1OPRK1GPR119STSACHE
SCHEMBL5231362 0.82 MEN1 (0.44)
SCHEMBL5232600 0.81 OPRD1 (0.44) OPRD1OPRK1GPR119STSACHE
SCHEMBL5225612 0.80 OPRD1 (0.42) OPRD1OPRK1GPR119STSACHE
SCHEMBL1049597 0.80 OPRD1 (0.49) OPRD1OPRK1GPR119STSACHE
SCHEMBL29247221 0.80 OPRD1 (0.43) OPRD1OPRK1GPR119STSACHE
SCHEMBL5228906 0.80 OPRD1 (0.43) OPRD1OPRK1GPR119STSACHE
SCHEMBL19124768 0.79 OPRD1 (0.46) OPRD1OPRK1GPR119STSACHE
SCHEMBL28607334 0.79 OPRD1 (0.43) OPRD1OPRK1GPR119STSACHE
SCHEMBL5230102 0.78 P2RX7 (0.46) P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001970-B1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER (US) 2007-03-07 EP disclosed
US-6953791-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-11 US disclosed
US-6951850-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-04 US disclosed
US-6924280-B2 Dipeptide derivatives PFIZER INC. (US) 2005-08-02 US disclosed
US-RE38524-E1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2004-06-01 US disclosed
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure CARPINO PHILIP ALBERT (US) 2004-01-15 US disclosed
US-20040006063-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2004-01-08 US disclosed
US-20030216399-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2003-11-20 US disclosed
US-6525047-B2 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair PFIZER INC. 2003-02-25 US disclosed
US-6432945-B1 Dipeptide derivatives PFIZER INC. 2002-08-13 US disclosed
US-6433171-B1 FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS PFIZER INC. 2002-08-13 US disclosed
US-6429313-B2 Dipeptide derivatives PFIZER INC. 2002-08-06 US disclosed
US-20020065284-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-05-30 US disclosed
US-20020042415-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-04-11 US disclosed
US-20020002165-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-01-03 US disclosed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 US disclosed
US-6251902-B1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2001-06-26 US disclosed
EP-1001970-A1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER INC. (US) 2000-05-24 EP disclosed
WO-1998058947-A1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER INC. (US) 1998-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure GHSR, GHRHR, GIPR OPRD1 802/4885OPRK1 758/4885GPR119 59/4885
US-20020042415-A1 Dipeptide derivatives GIPR, GHRHR, GHSR OPRD1 730/4885OPRK1 941/4885GPR119 53/4885
US-20010041703-A1 Dipeptide derivatives GIPR, GHRHR, GHSR OPRD1 728/4885OPRK1 1104/4885GPR119 55/4885
US-20020002165-A1 Dipeptide derivatives GIPR, GHRHR, GHSR OPRD1 730/4885OPRK1 941/4885GPR119 53/4885
US-20040006063-A1 Dipeptide derivatives GIPR, GHRHR, GHSR OPRD1 958/4885OPRK1 1042/4885GPR119 40/4885
US-20030216399-A1 Dipeptide derivatives GIPR, GHRHR, GHSR OPRD1 730/4885OPRK1 941/4885GPR119 53/4885
US-20020065284-A1 Dipeptide derivatives GIPR, GHRHR, GHSR OPRD1 730/4885OPRK1 941/4885GPR119 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.